Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Leonie Saft
Megakaryocytes Harbour the Del(5q) Abnormality Despite Complete Clinical and Cytogenetic Remission Induced by Lenalidomide Treatment
British Journal of Haematology
Hematology
Perturbations of the Endocannabinoid System in Mantle Cell Lymphoma: Correlations to Clinical and Pathological Features
Oncoscience
Cancer Research
Oncology
Related publications
Patients With Del(5q) MDS Who Fail to Achieve Sustained Erythroid or Cytogenetic Remission After Treatment With Lenalidomide Have an Increased Risk for Clonal Evolution and AML Progression
Annals of Hematology
Medicine
Hematology
Diagnosis of Del(5q) MDS, 14 Years After JAK-2 Positive PV Appearance: Complete Remission of Both Diseases With Lenalidomide Monotherapy
Mediterranean Journal of Hematology and Infectious Diseases
Infectious Diseases
Hematology
FISH and SNP-A Karyotyping in Myelodysplastic Syndromes: Improving Cytogenetic Detection of Del(5q), Monosomy 7, Del(7q), Trisomy 8 and Del(20q)
Leukemia Research
Cancer Research
Oncology
Hematology
Clonal Heterogeneity in the 5q- Syndrome: P53 Expressing Progenitors Prevail During Lenalidomide Treatment and Expand at Disease Progression
Haematologica
Hematology
Lenalidomide in 5q Minus Myelodysplastic Syndrome: How Long Is Enough?
Annals of Hematology
Medicine
Hematology
Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide
Haematologica
Hematology
A Critical Role for Phosphatase Haplodeficiency in the Selective Suppression of Deletion 5q MDS by Lenalidomide
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Low-Dose Lenalidomide Plus Cytarabine Induce Complete Remission That Can Be Predicted by Genetic Profiling in Elderly Acute Myeloid Leukemia Patients
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Extended Survival and Reduced Risk of AML Progression in Erythroid-Responsive Lenalidomide-Treated Patients With Lower-Risk Del(5q) MDS
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology